Jefferies Lowers Price Target for Arbutus Biopharma Due to Higher Appeal Probability
Jefferies has lowered its price target for Arbutus Biopharma Corporation (ABUS) from $7.00 to $5.50, citing an increased likelihood of Moderna winning its appeal, which could reduce ABUS's potential $1.3 billion payment. The firm maintains a Buy rating despite the downgrade. Arbutus reported Q4 and full-year 2025 financial results, including a net loss of $33.5 million and $91.5 million in cash and investments.
Topics: Arbutus Biopharma biotech stocks Jefferies litigation price target